Challenges in management of the Boston Keratoprosthesis Type 1.
AI Summary
This review highlights improved KPro outcomes but emphasizes persistent glaucoma challenges, crucial for managing high-risk corneal disease patients.
Abstract
Purpose of review: The Boston Keratoprosthesis Type 1 was pioneered by Claes Dohlman several decades ago. Since its inception, the device has undergone multiple revisions to address challenges associated with retroprosthetic membrane formation, retention, extrusion, stromal melt and endophthalmitis. Although visual outcomes and retention rates have improved, challenges, especially glaucoma, remain.
Recent findings: The Boston Keratoprosthesis Type I device has seen an increase in popularity because of the improvement in rates of retention and visual rehabilitation. Recent outcome studies have allowed clinicians to identify diagnoses and indications that can lead to more favorable results with the Boston Keratoprosthesis Type I device.
Summary
The Boston Keratoprosthesis Type I device continues to play a vital role in visual rehabilitation for eyes with very low chance of realistic allograft survival -- such as in eyes where corneal grafting is considered high-risk: eyes with corneal limbal stem cell failure, extensive deep corneal stromal neovascularization, and multiple allograft failures. This review article summarizes the perioperative and postoperative challenges, as well as other considerations associated with the device.
MeSH Terms
Shields Classification
Key Concepts5
Although visual outcomes and retention rates for the Boston Keratoprosthesis Type 1 device have improved, challenges, especially glaucoma, remain.
The Boston Keratoprosthesis Type I device has seen an increase in popularity due to improved rates of retention and visual rehabilitation.
Recent outcome studies have allowed clinicians to identify diagnoses and indications that can lead to more favorable results with the Boston Keratoprosthesis Type I device.
The Boston Keratoprosthesis Type I device plays a vital role in visual rehabilitation for eyes with a very low chance of realistic allograft survival, such as in eyes where corneal grafting is considered high-risk (e.g., corneal limbal stem cell failure, extensive deep corneal stromal neovascularization, and multiple allograft failures).
The Boston Keratoprosthesis Type 1 device has undergone multiple revisions to address challenges associated with retroprosthetic membrane formation, retention, extrusion, stromal melt, and endophthalmitis since its inception.
Related Articles5
Lifelong experience of modified osteo-odonto-keratoprosthesis implantation over 50 years.
Cohort StudyClinical characteristics and mortality rates for suprachoroidal hemorrhage: seven-year experience at a tertiary eye center.
Case SeriesTime to achieve best postoperative visual acuity following Boston keratoprosthesis surgery.
Retrospective StudiesPost-traumatic angle recession glaucoma: a risk factor for bleb failure after trabeculectomy.
Cohort StudyThe success and survival of repeat corneal grafts.
Case SeriesIs this article assigned to the wrong chapter(s)? Let us know.